Mantomed

Memantine Hydrochloride, the active ingredient in Mantomed, is an NMDA receptor antagonist presented as an oral tablet for oral use. It is used to treat moderate to severe Alzheimer’s disease in adults.

GNH USA supplies Mantomed as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mantomed is an NMDA receptor antagonist indicated for the treatment of Alzheimer’s disease, a neurodegenerative disorder affecting cognition and daily function.

- Alzheimer’s disease: improves cognition, global functioning and behavioral symptoms in patients with moderate to severe disease.

Memantine is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Dizziness: sensation of light‑headedness or unsteadiness. - Headache: mild to moderate pain in the head region. - Constipation: reduced bowel movements or hard stools. - Confusion: transient disorientation or difficulty concentrating. - Somnolence: increased sleepiness or fatigue.

Serious or Rare Side Effects: - Seizures: uncontrolled convulsive episodes requiring immediate medical attention. - Allergic reactions: rash, itching, swelling, or anaphylaxis. - Stevens‑Johnson syndrome: severe skin blistering and mucosal involvement. - Hepatic dysfunction: elevated liver enzymes or hepatitis. - Cardiac arrhythmia: irregular heart rhythm that may be symptomatic.

Before initiating Mantomed, clinicians should evaluate patient‑specific factors and monitor for potential risks.

- Renal impairment: adjust dose or monitor renal function regularly. - Hepatic impairment: use with caution and assess liver enzymes. - History of seizures: monitor closely for increased seizure activity. - Concomitant NMDA agonists: avoid co‑administration due to antagonistic interaction. - Pregnancy and lactation: safety not established; weigh benefits against potential risks. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Memantine may interact with other medicines that affect the NMDA pathway or central nervous system.

Major Interactions (Avoid): - Amantadine: combined NMDA antagonism can increase neuropsychiatric effects. - Dextromethorphan: additive CNS depression and confusion. - Ketamine: heightened risk of severe dizziness and hallucinations.

Moderate Interactions (Monitor Closely): - Anticholinergic agents: may reduce cognitive benefits of memantine. - CNS depressants (e.g., benzodiazepines): monitor for excessive sedation. - Antihypertensives: possible additive blood pressure lowering; observe blood pressure regularly.